Phase 2 N=47 Medtronic Reveal XT Study
Atrial Fibrillation
Primary: Number of ATA (Atrial Tachyarrhythmias) Episodes and Burden, Determined at Defined Postoperative Intervals — 20,878; 1,034 ATA episodes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Effects of Dronabinol (Oral THC) on Cannabis Use
Marijuana Smoking
Primary: Marijuana Self-administration - Progressive Ratio — 5.2; 4.5; 4.4 Progressive Ratios Completed
Phase 2 N=24 The Effect of Prescription Medications in Marijuana Users
Marijuana Abuse
Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
Phase 2 N=54 723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover
Rhinitis, Allergic, Seasonal
Primary: Weighted Mean TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3 — 4.9; 4.2; 3.6; 3.5 Score on…
Phase 2 N=12 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
Vaginal Cancer · Cervical Cancer · Anal Cancer
Primary: Maximum Tolerated Dose (MTD) — 2 # of cells x 10^11
Phase 2 N=293 A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
Psoriasis
Primary: Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 16 — 7.1; 34.1; 61.0; 78.6 percentage of participants…
Phase 2 N=16 Cognitive Impact of Pomegranate Polyphenols Following Ischemic Stroke
Stroke
Primary: Change From Baseline Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score — 6.86; 1.29 standard score change
Phase 2 N=20 Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence
Cannabis Dependence · Alcohol Dependence · Cannabis Use Disorder
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — 198.3; 55.9 ng/mg
Phase 2 N=12 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Dermatomyositis · Polymyositis
Primary: Specific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI). — 7 Participants
Phase 2 N=16 Biomarkers in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: PANSS Total — 77.9; 80 units on a scale — p=0.02
Phase 2 N=59 BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC
Lung Cancer
Primary: 8 Week Progression-Free Survival Rate (i.e. Disease Control Rate) — 20 Participants
Phase 2 N=14 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Uveal Melanoma
Primary: Number of Participants With Complete Response (CR) — 13; 0 Participants
Phase 2 N=19 Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Osteosarcoma Metastatic
Primary: The Study Medication Was to be Considered Effective if the Population Response Rate Was Found to be Greater Than 20% and Individuals Who Demonstrated a CR or PR or Whose…
Phase 2 N=36 Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
Alzheimer's Disease
Primary: One-card Learning (OCL) Measurement Over 12 Weeks of Treatment — 0.954; 0.942; 0.822; 0.969 Score on a scale
Phase 2 N=27 Safety and Efficacy of Ranibizumab for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Number of Participants With Non-severe Ocular Adverse Events — 9; 5; 4; 3 Participants — p=<0.05